Adage Capital Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Adage Capital Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-200,000	Closed	-$5.08M	–	838
2020 Q2	$5.08M	Sell	200,000 -50,000	-20%	-$1.08M	0.01%	619
2020 Q1	$4.59M	Sell	250,000 -150,000	-38%	-$2.92M	0.01%	581
2019 Q4	$8.81M	Sell	400,000 -2,150,000	-84%	-$43.3M	0.02%	556
2019 Q3	$36.6M	Sell	2,550,000 -250,000	-9%	-$3.57M	0.09%	254
2019 Q2	$44.1M	Sell	2,800,000 -250,000	-8%	-$3.4M	0.11%	224
2019 Q1	$44.7M	Hold	3,050,000	–	–	0.11%	216
2018 Q4	$32.6M	Buy	3,050,000 +600,000	+24%	+$7.89M	0.09%	245
2018 Q3	$37.4M	Hold	2,450,000	–	–	0.08%	272
2018 Q2	$30M	Buy	2,450,000 +725,000	+42%	+$9.11M	0.07%	313
2018 Q1	$16.5M	Sell	1,725,000 -250,000	-13%	-$2.7M	0.04%	445
2017 Q4	$17.8M	Buy	+1,975,000	New	+$14.5M	0.04%	433

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Adage Capital Partners's DRNA Position: Q3 2020 in Review

Adage Capital Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 200,000 shares — an estimated $5.08M sold.

Adage Capital Partners first reported a position in DRNA in Q4 2017 and held it in 11 quarters. The position peaked at $44.7M in Q1 2019. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

Adage Capital Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Adage Capital Partners sold 200,000 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $5.08M.
Adage Capital Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and held it in 11 quarters.
Adage Capital Partners's Dicerna Pharmaceuticals, Inc. position peaked at $44.7M in Q1 2019.
172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on Adage Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.